Rubén Tommasi
Io Therapeutics (United States)(US)
Publications by Year
Research Areas
Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Chemical Synthesis and Analysis, Bacterial Genetics and Biotechnology, HIV/AIDS drug development and treatment
Most-Cited Works
- → ESKAPEing the labyrinth of antibacterial discovery(2015)601 cited
- → Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class(1998)295 cited
- → ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii(2017)267 cited
- → Trends and Exceptions of Physical Properties on Antibacterial Activity for Gram-Positive and Gram-Negative Pathogens(2014)251 cited
- → Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors(2011)153 cited
- → Rational design of a new antibiotic class for drug-resistant infections(2021)137 cited
- → Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of Cathepsin B through Structure-Based Drug Design(2001)136 cited
- → Optimization of Halopemide for Phospholipase D2 inhibition(2007)100 cited
- → Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases(2015)100 cited
- → Structure-Based Design of HIV Protease Inhibitors: Sulfonamide-Containing 5,6-Dihydro-4-hydroxy-2-pyrones as Non-Peptidic Inhibitors(1996)96 cited